The New York Times Howard Lotsof Dies at 66, died on Jan. 31 at a hospital near his home on Staten Island. The cause was liver cancer, his wife, Norma said.
…Virtually from that day 48 years ago when he first tried ibogaine, Mr. Lotsof became perhaps its leading advocate, lobbying public officials, pharmaceutical companies and independent researchers to investigate its efficacy. In the mid-1980s, he persuaded a Belgian company to manufacture ibogaine in capsule form and begin offering it to addicts in the Netherlands.
“His great achievement,” said Kenneth Alper, an associate professor of psychiatry and neurology at the New York University School of Medicine, “was in inducing the National Institute on Drug Abuse to undertake a research project on ibogaine that produced scores of peer-reviewed publications and paved the way for F.D.A. approval of a clinical trial.”
The Food and Drug Administration did approve the trial, Dr. Alper said, but it was never completed because of contractual disputes and lack of financing. Ibogaine remains banned by the federal government.
“In the uncontrolled environments in which ibogaine is typically used, clinics or nonmedical settings,” Dr. Alper said, “the observations indicate that there is a resolution of withdrawal, meaning the addict is detoxified and no longer has withdrawal symptoms and is no longer physically dependent.” Scientifically controlled testing is needed, he said.
Dutch video with Howard: A novel antiaddictice medication: ibogaine.